This application requests support for personnel, operating expenses and travel related to the conduct of Southwest Oncology Group cooperative clinical trials at Temple University and its CGOPs. This support is aimed at providing initial partial funding for the entrance of Temple University into clinical cooperative group research. The support will also enhance the already substantial leadership contribution by Dr. Macdonald to the Southwest Oncology Group. Dr. Macdonald has been Chairman of the GI Committee since 1985 and has served in both scientific and administrative leadership roles for the group. The Temple University Comprehensive Cancer Center, a new entity in clinical cancer care and research, was opened in September of 1989 and has served as an introduction of the Temple University Health Sciences Center to clinical cancer research. Because it was recognized that it would take substantial organizational effort and personnel investment to develop a large SWOG accrual base at Temple, accrual to the Southwest Oncology group was enhanced by the recruitment of CGOPs for association with Temple. This strategy has resulted in a total registration of 79 cases as of 12/31/91. The breakdown of accrual over time demonstrates a positive trend. In the period 1/1/90 - 12/31/90, 34 cases were accrued. Between 1/1/90 and 12/31/91, the accrual was 45 patients. These results have been attained even though the two most recently approved CGOPs (Columbia University and Desert Hospital) have not yet accrued any patients. These results have been achieved without any designated funding for clinical trials support from the Southwest Oncology Group. With the funding requested in this application, the Temple University Cancer Program intends to increase accrual to Southwest Oncology Group studies. A special effort will be made to expand accrual onto Southwest Oncology Group studies from the large minority community which Temple serves.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA058415-02
Application #
2099105
Study Section
Cancer Clinical Investigation Review Committee (CCI)
Project Start
1993-02-10
Project End
1997-12-31
Budget Start
1994-01-01
Budget End
1994-12-31
Support Year
2
Fiscal Year
1994
Total Cost
Indirect Cost
Name
Temple University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Philadelphia
State
PA
Country
United States
Zip Code
19122
Carson 3rd, William E; Unger, Joseph M; Sosman, Jeffrey A et al. (2014) Adjuvant vaccine immunotherapy of resected, clinically node-negative melanoma: long-term outcome and impact of HLA class I antigen expression on overall survival. Cancer Immunol Res 2:981-7
Gordon, M A; Gundacker, H M; Benedetti, J et al. (2013) Assessment of HER2 gene amplification in adenocarcinomas of the stomach or gastroesophageal junction in the INT-0116/SWOG9008 clinical trial. Ann Oncol 24:1754-61
Sosman, Jeffrey A; Moon, James; Tuthill, Ralph J et al. (2011) A phase 2 trial of complete resection for stage IV melanoma: results of Southwest Oncology Group Clinical Trial S9430. Cancer 117:4740-06
Scosyrev, Emil; Ely, Benjamin W; Messing, Edward M et al. (2011) Do mixed histological features affect survival benefit from neoadjuvant platinum-based combination chemotherapy in patients with locally advanced bladder cancer? A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int 108:693-9
Chu, David Z J; Hussey, Michael A; Alberts, David S et al. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), randomized and placebo controlled: the importance of multiple luminal lesions. Clin Colorectal Cancer 10:310-6
Harigopal, Malini; Barlow, William E; Tedeschi, Greg et al. (2010) Multiplexed assessment of the Southwest Oncology Group-directed Intergroup Breast Cancer Trial S9313 by AQUA shows that both high and low levels of HER2 are associated with poor outcome. Am J Pathol 176:1639-47
Albain, Kathy S; Barlow, William E; Shak, Steven et al. (2010) Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial. Lancet Oncol 11:55-65
Albain, Kathy S; Barlow, William E; Ravdin, Peter M et al. (2009) Adjuvant chemotherapy and timing of tamoxifen in postmenopausal patients with endocrine-responsive, node-positive breast cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:2055-63
Sonpavde, Guru; Goldman, Bryan H; Speights, V O et al. (2009) Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115:4104-9
Tubbs, Raymond; Barlow, William E; Budd, G Thomas et al. (2009) Outcome of patients with early-stage breast cancer treated with doxorubicin-based adjuvant chemotherapy as a function of HER2 and TOP2A status. J Clin Oncol 27:3881-6

Showing the most recent 10 out of 54 publications